Helicobacter pylori (H.pylori) infection is an infectious disease with a prevalence rate of up to 50% worldwide. It can cause dyspepsia, gastritis, peptic ulcer disease and gastric cancer. H.pylorieradication treatment can effectively control disease progression and reduce risk of the conditions. However, the escalating trend of antibiotic resistance presents a global challenge for H.pylori eradication. Though decreasing in developed countries, the prevalence of H.pylori infection remains high in developing countries, causing a major public health burden. This clinical practice guideline (CPG) is made to provide guidance on the pharmacological treatment of H.pylori infection. This CPG is developed following the World Health Organization′s recommended process, adopting grading of recommendations assessment, development, and evaluation (GRADE) in assessing evidence quality and utilizing evidence to decision framework to formulate clinical recommendations, minimising bias and increasing transparency of the CPG development process. The Reporting Items for Practice Guidelines in Healthcare (RIGHT) statement and Appraisal of Guidelines for Research and EvaluationⅡ(AGREE Ⅱ) are used as reporting and conduct guide to ensure its completeness and transparency. This CPG contains 12 recommendations concerning pharmacological treatment for H. pylori eradication. Among them, it is worth highlighting that bismuth preparations are safe, effective and inexpensive, consequently making bismuth quadruple therapy a preferred choice for initial and rescue treatments. In empirical treatment, high dose dual therapy is equally effective as bismuth quadruple therapy. The 12 recommendations in this CPG are formed with consideration to stakeholders′ values and preferences, resource use, feasibility and acceptability. These recommendations are generalisable to resource limited settings with similar antibiotic resistance pattern as China, and status with comparable sociological and technical challenges.